Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use

Inflamm Bowel Dis. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Certolizumab Pegol
  • Crohn Disease / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage*
  • In Vitro Techniques
  • Infliximab
  • Male
  • Polyethylene Glycols / administration & dosage*
  • Recurrence
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Polyethylene Glycols
  • Infliximab
  • Certolizumab Pegol